Mucinous Cystadenocarcinoma in Breast: Complicated with Lymph Node, Thoracic Wall Metastasis, and Contralateral Triple Negative Breast Cancer: A Case Report

Abstract Background: Mucinous cystadenocarcinoma of the breast is a very rare and special type adenocarcinoma of the mammary tract. We report a rare case of mucinous cystadenocarcinoma of the breast with an unfavourable prognosis which was confirmed after surgical resection pathologically. Case summary: At low power appearance, the tumor formed mucus-filled spaces of varying sizes, and with mucus-rich tumor cells lining the walls. The tumor cells were arranged in papillary structures. At high magnification, the tumor cells shown moderate to severe atypia, which were most of simple columnar cells with nuclei in the base and cytoplasm rich in mucin. In some areas, tumor cells proliferated, stratified, and clustered that protruded into the cyst cavity, or formed papillary structures with thin fibrovascular core. Immunohistochemical staining showed cytoplasm CK7 strong positive of tumor cells and cytoplasm negative of CK20, PAX-8 and CDX2, which could exclude metastatic tumors from ovary and intestine. And the tumor cells also demonstrated the basal-like characters such as negative for ER, PR, HER-2 (triple-negative), CK5/6 focal positive, EGFR positive. Besides, a triple negative breast cancer with basal-like features, lymph node, thoracic wall metastasis of mucinous cystadenocarcinoma was found. Conclusion: Mucinous cystadenocarcinoma of the breast usually have a favorable prognosis, but in this case, it happened lymph node, thoracic wall metastasis, therefore, it needs extra attention of clinical workers.

Download Full-text

Incidence of triple negative breast cancer at Rajendra Institute of Medical Sciences, Ranchi

International Surgery Journal ◽

10.18203/2349-2902.isj20194045 ◽

2019 ◽

Vol 6 (9) ◽

pp. 3134

Author(s):

Priyanka Kumari ◽

Sumit Bhaskar ◽

Rajiv Ranjan ◽

Dipendra Kumar Sinha

Keyword(s):

Breast Cancer ◽

Lymph Node ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Tumour Size ◽

Progesterone Receptors ◽

Prognostic Index ◽

Axillary Lymph ◽

Receptor Status ◽

Her 2

Background: Breast carcinoma is the second most common carcinoma in women and accounts for 22% of all female cancer, which is more than twice the prevalence of cancer in women at any other site. Triple negative breast cancer, i.e., negative expression of oestrogen and progesterone receptors and HER2/neu receptors and accounts for approximately 10-17% of all breast carcinomas, is biologically aggressive, resistant to conventional cytotoxic chemotherapy treatment, and is associated with reduced survival compared to other subtypes of breast cancer.Methods: History, local examination, Various investigations like: FNAC of breast lump and axillary lymph node, USG of breasts and axilla, USG of whole abdomen and pelvis, Chest X-ray PA View etc, ER/PR and HER-2/neu status on the specimen sent for HPE were done. The prognostic implications on ER, PR and HER-2/neu receptors were assessed indirectly with the help of Nottingham prognostic index (NPI)).Results: A statistically significant correlation of ER/PR receptor status was found with tumour size, no. of lymph nodes, tumour grade and NPI, whereas HER2/neu receptor status had a statistically significant correlation with tumour size and no. of lymph node involved. Incidence of triple negative breast cancer in this Institute is 20%.Conclusions: ER, PR and HER2/neu receptor status is highly important predictor in cases of carcinoma breast which necessitates routine evaluation of these receptor statuses for better management of disease.

Download Full-text

Reproductive and hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast cancer

Cancer ◽

10.1002/cncr.23786 ◽

2008 ◽

Vol 113 (7) ◽

pp. 1521-1526 ◽

Cited By ~ 80

Author(s):

Amanda I. Phipps ◽

Kathleen E. Malone ◽

Peggy L. Porter ◽

Janet R. Daling ◽

Christopher I. Li

Keyword(s):

Breast Cancer ◽

Risk Factors ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Her 2

Download Full-text

Differential expression of cyclin A2 in triple negative breast cancer.

10.31219/osf.io/abq4x ◽

2021 ◽

Author(s):

Shahan Mamoor

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Differential Expression ◽

Tumor Cells ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Differentially Expressed ◽

Primary Tumors ◽

Ductal Cells ◽

Cyclin A2

Women diagnosed with triple negative breast cancer can benefit neither from endocrine therapy nor from HER2-targeted therapies (1). We mined published microarray datasets (2, 3) to determine in an unbiased fashion and at the systems level genes most differentially expressed in the primary tumors of patients with breast cancer. We report here significant differential expression of the gene encoding cyclin A2, CCNA2, when comparing the tumor cells of patients with triple negative breast cancer to normal mammary ductal cells (2). CCNA2 was also differentially expressed in bulk tumor in human breast cancer (3). CCNA2 mRNA was present at significantly increased quantities in TNBC tumor cells relative to normal mammary ductal cells. Analysis of human survival data revealed that expression of CCNA2 in primary tumors of the breast was correlated with overall survival in patients with basal-like type cancer, while within triple negative breast cancer, primary tumor expression of CCNA2 was correlated with overall survival in patients with basal-like 1, basal-like 2, and mesenchymal subtype disease. CCNA2 may be of relevance to initiation, maintenance or progression of triple negative breast cancers.

Download Full-text

Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients

PLoS ONE ◽

10.1371/journal.pone.0253176 ◽

2021 ◽

Vol 16 (6) ◽

pp. e0253176

Author(s):

Katsuhiro Yoshikawa ◽

Mitsuaki Ishida ◽

Hirotsugu Yanai ◽

Koji Tsuta ◽

Mitsugu Sekimoto ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Tumor Cells ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Expression Profiles ◽

Histological Grade ◽

Relapse Free Survival ◽

Free Survival ◽

Antitumor Immunotherapy

Introduction CD155 is an immune checkpoint protein. Its overexpression is an indicator of poor prognosis in some types of cancer. However, the significance of CD155 expression in patients with triple-negative breast cancer, and the relationship between CD155 and programmed death-ligand 1 (PD-L1) expression, have not yet been analyzed in detail. Methods Using immunohistochemical staining and tissue microarrays, we analyzed the expression profiles of CD155 and PD-L1 in 61 patients with triple-negative breast cancer. Relapse-free survival and overall survival rates were compared according to CD155 expression. The correlation between CD155 expression and clinicopathological factors, including PD-L1 expression (using SP142 and 73–10 assays), was also examined. Results CD155 expression was noted in 25 patients (41.0%) in this cohort. CD155 expression did not correlate with pathological stage, histological grade, Ki-67 labeling index, or stromal tumor-infiltrating lymphocytes. Only PD-L1 expression in tumor cells by SP142 assay significantly correlated with CD155 expression (p = 0.035); however, PD-L1 expression in tumor cells by 73–10 assay did not show a correlation (p = 0.115). Using the 73–10 assay, 59% of patients showed CD155 and/or PD-L1 expression in tumor cells. Moreover, using the SP142 assay, 63.3% of patients showed CD155 and/or PD-L1 expression in immune cells. CD155 expression did not correlate with either relapse-free survival or overall survival (p = 0.485 and 0.843, respectively). Conclusions CD155 may be a novel target for antitumor immunotherapy. The results of this study indicate that CD155 may expand the pool of candidates with triple-negative breast cancer who could benefit from antitumor immunotherapy.

Download Full-text

How shall we treat locally advanced triple negative breast cancer?

F1000Research ◽

10.12688/f1000research.20509.2 ◽

2020 ◽

Vol 8 ◽

pp. 1649

Author(s):

Paulo Luz ◽

David Dias ◽

Ana Fortuna ◽

Luis Bretes ◽

Beatriz Gosalbez

Keyword(s):

Breast Cancer ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Locally Advanced ◽

Surrogate Marker ◽

Metastatic Breast ◽

Complete Response ◽

Number Of Patients ◽

Her 2 ◽

Near Future

Triple negative breast cancer (TNBC) has been shown to respond to neoadjuvant chemotherapy (NACT). It has been established that achieving pathological complete response (pCR) for certain aggressive subtypes of breast cancer, including HER-2 (over-expressed) and TNBC, provides an important surrogate marker for predicting long-term clinical response and survival outcomes. How to increase the number of patients that achieve pCR remains challenging. Platinum-based NACT seems to be part of the solution and capecitabine, an active drug in metastatic breast cancer, but not a standard one in earlier stages may have found its place in the adjuvant setting. In the near future immunotherapy can play a role in early TNBC

Download Full-text

Antiangiogenic therapy for breast cancer with triple negative phenotype

Modern Oncology ◽

10.26442/18151434.2021.1.200763 ◽

2021 ◽

Vol 23 (1) ◽

pp. 88-92

Author(s):

Inna P. Ganshina ◽

Kristina A. Ivanova ◽

Olga O. Gordeeva ◽

Aleksandr V. Arkhipov ◽

Liudmila G. Zhukova

Keyword(s):

Breast Cancer ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Malignant Tumors ◽

Antiangiogenic Therapy ◽

Treatment Strategies ◽

Her 2 ◽

Triple Negative Phenotype ◽

The Impact ◽

Negative Phenotype

Triple-negative breast cancer is 1024% of all cases of breast cancer and is characterized by the absence of estrogen, progesterone, and HER-2 receptors in the tumor. The therapy of this illness is a difficult clinical case. In contrast to hormone-positive and HER-2-positive phenotypes, in which we successfully use targeted drugs (antiestrogens and anti-HER-2 drugs), for triple-negative breast cancer we have not had such targets for a long time. Thus, despite the impressive results of immunotherapy of triple-negative breast cancer, there remains a fairly large group of patients with negative PD-L1 status, for whom it is necessary to develop other treatment strategies. One of the approaches in the treatment of malignant tumors includes not the impact on tumor cells, but the process of angiogenesis. Antiangiogenic drugs have positively proven themselves in the treatment of a large number of malignant tumors but are underestimated for breast cancer (including triple-negative phenotype). The use of bevacizumab in combinations with cytostatic drugs in breast cancer therapy (including triple-negative breast cancer) has been studied in a large number of clinical trials but was undeservedly forgotten in some countries due to the revoked FDA registration. This review presents the role of bevacizumab in the treatment of patients with triple-negative breast cancer and suggests the conditions when the administration of this drug is justified and leads to better results.

Download Full-text